Health Canada approves drug that treats hot flashes for use by breast cancer patients CTV NewsMuna Al-Khaifi: A New Non-Hormonal Option for Vasomotor Symptoms in Breast Cancer Survivors OncodailyLYNKUET® (elinzanetant) Receives Expanded Market Authorization in Canada for Treatment of Moderate to Severe Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy (AET) Related to Breast Cancer Business WireHealth Canada’s nod brings hope for breast cancer patients Winnipeg SunMHRA authorizes Bayer’s Lynkuet for wider VMS use The Pharma Letter